Bioavailability of Three Rufinamide Oral Suspensions Compared With the Marketed 400-mg Tablet Formulation: Results From a Randomized-Sequence, Open-Label, Four-Period, Four-Sequence Crossover Study in Healthy Subjects

✍ Scribed by David John Critchley; Jagadeesh Aluri; Peter Boyd; Matthew Whayman; Milind Narurkar; Hugh Delargy; Francesco Bibbiani

• Book ID: 113544336
• Publisher: Elsevier Science
• Year: 2011
• Tongue: English
• Weight: 357 KB
• Volume: 33
• Category: Article
• ISSN: 0149-2918
• DOI: 10.1016/j.clinthera.2011.01.016